Short answer
Cytek Biosciences, Inc. (CTKB) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $52M (up 1.5% year over year) with net income of −$5M.
Q3 2025 key financials · XBRL
- Revenue
- $52M
- +1.5% YoY · +14.7% QoQ
- Net income
- −$5M
- −682.8% YoY · +1.9% QoQ
- Operating margin
- -17.6%
- Gross margin
- 52.7%
Source: XBRL data from the Cytek Biosciences, Inc. (CTKB) Q3 2025 10-Q on SEC EDGAR. USD.
Cytek Biosciences, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New tariff risk triggered by 2025 U.S. tariffs and foreign retaliation, increasing component costs and potentially reducing demand
- Most materially updated supply-chain risk: Coherent Agreement amended August 12, 2025, but other key suppliers lack long-term contracts
- Regulatory compliance exposure from tariffs and trade restrictions, including potential civil or criminal enforcement actions
- Near-term revenue volatility from six-month-or-longer instrument sales cycles and dependence on Aurora, Northern Lights, Aurora CS, and Aurora Evo
- Financial risk from foreign-currency exchange-rate fluctuations across international operations and manufacturing in China and Singapore
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Cytek Biosciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.